Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Originator Launches Opening Salvo In Bid To Have Dismissal Overturned
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
You may also be interested in...
Teva has been denied in its attempt to convince the US Supreme Court to re-examine long-running litigation with GSK over skinny-label carve-outs of generic indications. However, the generics firm has vowed to fight on as the case is returned to the district court level, while the wider off-patent industry weighs the impact of the latest decision.
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
As the US Supreme Court deliberates on whether to grant Teva’s petition to review its litigation with GSK over “skinny label” generics that carve out patented indications, Aziz Burgy, partner at Axinn, Veltrop & Harkrider LLP, talks to Generics Bulletin about the key issues at stake.